Skip to main content
. 2021 Dec;12(6):3061–3078. doi: 10.21037/jgo-21-748

Figure 3.

Figure 3

The correlation between genetic mutations in EIF2S2 and HCC prognosis using cBioPortal. (A) Changes in EIF2S2 in 39 (11%) LIHC patients [366]. There is no correlation between genetic mutations and various survival periods including the overall survival (P=0.150) (B), disease-free survival (P=0.463) (C), progression-free survival (P=0.855) (D), and disease-specific survival (P=0.338) (E) in HCC patients. EIF2S2, eukaryotic translation initiation factor 2 subunit beta; HCC, hepatocellular carcinoma; LIHC, liver hepatocellular carcinoma.